Advertisement
STTK vs TRVI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STTK is a Hold and TRVI is a Hold.
STTK's Stochastic Oscillator remains in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STTK's RSI Indicator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +11.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where STTK advanced for three days, in 227 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
STTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STTK as a result. In 83 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for STTK turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
The 50-day moving average for STTK moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for STTK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.196) is normal, around the industry mean (3.498). P/E Ratio (-10.500) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. STTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for TRVI turns positive, indicating new upward trend
TRVI saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 74 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRVI's RSI Indicator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on October 20, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
TRVI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in 240 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for TRVI moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TRVI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TRVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.350) is normal, around the industry mean (3.498). P/E Ratio (-40.943) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
STTK | TRVI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 23 | |
SMR RATING 1..100 | 97 | 95 | |
PRICE GROWTH RATING 1..100 | 56 | 45 | |
P/E GROWTH RATING 1..100 | 14 | 27 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TRVI's Valuation (5) in the Pharmaceuticals Major industry is in the same range as STTK (23) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.
TRVI's Profit vs Risk Rating (23) in the Pharmaceuticals Major industry is significantly better than the same rating for STTK (100) in the null industry. This means that TRVI’s stock grew significantly faster than STTK’s over the last 12 months.
TRVI's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as STTK (97) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.
TRVI's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as STTK (56) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.
STTK's P/E Growth Rating (14) in the null industry is in the same range as TRVI (27) in the Pharmaceuticals Major industry. This means that STTK’s stock grew similarly to TRVI’s over the last 12 months.
| STTK | TRVI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Advances ODDS (%) | 3 days ago 86% | 3 days ago 85% |
| Declines ODDS (%) | 7 days ago 87% | 17 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STTK’s FA Score shows that 2 FA rating(s) are green while TRVI’s FA Score has 3 green FA rating(s).
- STTK’s FA Score: 2 green, 3 red.
- TRVI’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STTK’s TA Score shows that 4 TA indicator(s) are bullish while TRVI’s TA Score has 5 bullish TA indicator(s).
- STTK’s TA Score: 4 bullish, 5 bearish.
- TRVI’s TA Score: 5 bullish, 5 bearish.
Price Growth
STTK (@Biotechnology) experienced а -11.33% price change this week, while TRVI (@Biotechnology) price change was +7.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
STTK is expected to report earnings on Mar 16, 2027.
TRVI is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
STTK and
Correlation & Price change
A.I.dvisor indicates that over the last year, STTK has been loosely correlated with GHRS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STTK jumps, then GHRS could also see price increases.
| Ticker / NAME | Correlation To STTK | 1D Price Change % | ||
|---|---|---|---|---|
| STTK | 100% | -2.81% | ||
| GHRS - STTK | 44% Loosely correlated | +1.56% | ||
| TRVI - STTK | 43% Loosely correlated | -2.61% | ||
| SLDB - STTK | 41% Loosely correlated | +2.14% | ||
| SNDX - STTK | 39% Loosely correlated | -0.63% | ||
| WHWK - STTK | 38% Loosely correlated | -4.35% | ||
More | ||||